<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_BostonU_App_1_Design skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:BostonU/App 1/Design</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><UL id="nav"><LI><A href="https://2015.igem.org/Team:BostonU">Home</A></LI><LI><A href="">Research</A></LI><LI><A href="https://2015.igem.org/Team:BostonU/Temporal_Control">Controlling Protein Activity</A></LI><LI><A href="https://2015.igem.org/Team:BostonU/Modeling">Experimental Design</A></LI><LI><A href="https://2015.igem.org/Team:BostonU/App_1/Motivation">Controlling Integrases and RDFs</A></LI><LI><A href="https://2015.igem.org/Team:BostonU/App_2/Motivation">Controlling saCas9</A></LI><LI><A href="https://2015.igem.org/Team:BostonU/Design">Functional Prototype</A></LI><LI><A href="https://2015.igem.org/Team:BostonU/Notebook/Protocols/Bacterial">Notebook</A></LI></UL><LI><A href="">iGEM Community</A></LI><LI><A href="https://2015.igem.org/Team:BostonU/Mammalian_synbio/Significance">Mammalian Synthetic Biology</A></LI><LI><A href="https://2015.igem.org/Team:BostonU/Interlab">Interlab Study</A></LI><LI><A href="https://2015.igem.org/Team:BostonU/Parts">Part Submissions</A></LI><LI><A href="">Outreach Initiatives</A></LI><LI><A href="https://2015.igem.org/Team:BostonU/Education/Building_with_Biology">Education</A></LI><LI><A href="https://2015.igem.org/Team:BostonU/Collaborations">Collaborations</A></LI><LI><A href="https://2015.igem.org/Team:BostonU/Industry">Industry</A></LI><LI><A href="">Acknowledgements</A></LI><LI><A href="https://2015.igem.org/Team:BostonU/Team">Our Team</A></LI><LI><A href="https://2015.igem.org/Team:BostonU/Attributions">Attributions</A></LI><LI><A href="https://2015.igem.org/Team:BostonU/Medals">Judging</A></LI><TABLE align="center" style="margin: 0px auto;"><TBODY><TR><TD><A href="https://2015.igem.org/Team:BostonU/App_1/Motivation" class="button">Motivation</A></TD><TD><A href="https://2015.igem.org/Team:BostonU/App_1/Design" class="button">Design</A></TD><TD><A href="https://2015.igem.org/Team:BostonU/App_1/Results" class="button">Results</A></TD></TR></TBODY></TABLE><H3>Design</H3><P>After looking into the literature, our team decided to split two integrases: TP901-1 and PhiC31, and their corresponding RDFs: orf7 and gp3 (respectively). These integrase-RDF pairs can recognize orthogonal sites, and therefore can be used alongside each other in a robust system.</P><P>We applied our <A href="https://2015.igem.org/Team:BostonU/Modeling" style="color:#FF9966;">split protein pipeline</A> to determine promising split locations for both integrases and RDFs. We chose 8 candidate integrase split sites and 4 candidate RDF split sites, and cloned these into our mammalian expression plasmid backbones that included fusion to our sets of dimerizable domains. We independently tested the functionality of these conditionally dimerizable proteins using fluorescent reporter plasmids.</P><P>For testing the functionality of our conditionally dimerizable integrases, we used a fluorescent reporter containing an inverted mRuby coding sequence flanked by two recombination sites that could be specifically recognized by the particular integrase (i.e. we used a reporter with TP901-1 recognizable sites for the split TP901-1 constructs, and a reporter with PhiC31 recognizable sites for the split PhiC31 constructs). We co-transfected this reporter with our pairs of plasmids that coded for our conditionally dimerizable split proteins, and assayed for fluorescent activity in the absence and presence of the drug. We expected that the “OFF” state (absence of inducer), there was no mRuby expression, whereas in the “ON” state (presence of inducer) there was mRuby expression.</P><P>For testing the functionality of our conditionally dimerizable RDFs, we used a similar fluorescent reporter containing an inverted mRuby coding sequence flanked by two recombination sites that could be specifically recognized by the particular RDF (i.e. we used a reporter with TP901-1+orf7 recognizable sites for the split orf7 constructs, and a reporter with PhiC31+gp3 recognizable sites for the split gp3 constructs). So, these recombination sites are different than the ones used in the integrase reporter. We co-transfected this reporter with our pairs of plasmids that coded for our conditionally dimerizable split proteins as well as with a plasmid that coded for the corresponding full integrase, and assayed for fluorescent activity in the absence and presence of the drug. We expected that the “OFF” state (absence of inducer), there was no mRuby expression, whereas in the “ON” state (presence of inducer) there was mRuby expression.</P></DIV></DIV></DIV></DIV></BODY></HTML>